1. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges

   • Grazyna Lipowska-Bhalla
   • David E. Gilham
   • Dominic G. Rothwell

   Review 22 April 2012 Pages: 953 - 962

   

2. Is an immune reaction required for malignant transformation and cancer growth?

   • Richmond T. Prehn
   • Liisa M. Prehn

   Perspectives Open access 18 May 2012 Pages: 963 - 966

   

3. Harmonization of the intracellular cytokine staining assay

   • Marij J. P. Welters
   • Cécile Gouttefangeas
   • Sjoerd H. van der Burg

   Original article Open access 22 May 2012 Pages: 967 - 978

   

4. Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes

   • Dongmei Lai
   • Fangyuan Wang
   • Lihe Guo

   Original article 27 November 2011 Pages: 979 - 989

   

5. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells

   • Tracy R. Daniels
   • Richard K. Leuchter
   • Manuel L. Penichet

   Original Article 30 November 2011 Pages: 991 - 1003

   

6. Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy

   • Fernanda V. Castro
   • Mariam Al-Muftah
   • Peter L. Stern

   Original Article 30 November 2011 Pages: 1005 - 1018

   

7. An immune-active tumor microenvironment favors clinical response to ipilimumab

   • Rui-Ru Ji
   • Scott D. Chasalow
   • Vafa Shahabi

   Original article 07 December 2011 Pages: 1019 - 1031

   

8. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient

   • An M. T. Van Nuffel
   • Daphné Benteyn
   • Aude Bonehill

   Original article 10 December 2011 Pages: 1033 - 1043

   

9. Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer

   • Kristoffer Watten Brudvik
   • Karen Henjum
   • Kjetil Taskén

   Original article 11 December 2011 Pages: 1045 - 1053

   

10. Collective action of hematopoietic cell subsets mediates anti-IL10R1 and CpG tumor immunity

    • Meng-Yun Chou
    • Cary D. Austin
    • Jeong M. Kim

    Original article 11 December 2011 Pages: 1055 - 1064

    

11. Activation-induced cell death of memory CD8+ T cells from pleural effusion of lung cancer patients is mediated by the type II Fas-induced apoptotic pathway

    • Heriberto Prado-Garcia
    • Susana Romero-Garcia
    • Jose Sullivan Lopez-Gonzalez

    Original Article 13 December 2011 Pages: 1065 - 1080

    

12. Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors

    • Hideyuki Nakashima
    • Kotaro Miyake
    • Kathryn C. Zoon

    Original article 13 December 2011 Pages: 1081 - 1092

    

13. Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes

    • Christina S. Mullins
    • Michael Linnebacher

    Original article 21 December 2011 Pages: 1093 - 1100

    

14. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues

    • Jurjen Tel
    • Stanleyson V. Hato
    • I. Jolanda M. de Vries

    Original article Open access 23 December 2011 Pages: 1101 - 1111

    

15. Exploiting antitumor immunity to overcome relapse and improve remission duration

    • Lei L. Chen
    • Xinjian Chen
    • Robert S. Benjamin

    Original article Open access 24 December 2011 Pages: 1113 - 1124

    

16. Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy

    • Katayoun Rezvani
    • Agnes S. M. Yong
    • A. John Barrett

    Original article 24 December 2011 Pages: 1125 - 1136

    

17. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer

    • Douglas G. McNeel
    • Heath A. Smith
    • Glenn Liu

    Original Article 31 December 2011 Pages: 1137 - 1147

    

18. Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy

    • Angela J. Ziebarth
    • Mildred A. Felder
    • Joseph P. Connor

    Short Communication 06 May 2012 Pages: 1149 - 1153